European Sovereignty Monitor

Industry, investment and R&D

CEPA warns China's rise in biotech discovery threatens transatlantic pharma edge

CEPA fellow Elly Rostoum argues China is climbing from biotech manufacturing into drug discovery, urging the US and Europe to preserve the translation-stage strengths that keep transatlantic pharma competitive.

Reported Opinion Abroad AI-drafted CEPA analysis, 24 September 2026

What the source does not establish. Does not establish any new EU policy, funding decision or company action; it states the author's own reading of a global industry trend.

Index score. No movement: no answer to who owns, who operates, whose law governs or who made the parts changes. Weight 0. No question moves: a published analysis, not an institutional act, on transatlantic biotech scale. European Sovereignty Index

How this item was made. Drafted by an AI system (Claude (Anthropic)) from the source cited above and published under the editor’s responsibility without a person reading it first. How the record is made

What the tags mean: VerifiedReportedAI-draftedAI-drafted, editor-readHuman-writtenWhat the tags mean

Previously in Industry, investment and R&D

ReportedAI-drafted Ukrainian founded defence roll up Uforce raises USD 700 million Series A ReportedAI-drafted Munich's SE3 raises USD 30 million Series A for battlefield spatial AI ReportedAI-drafted SoftBank leads USD 500 million round for Munich's Agile Robots

All Industry, investment and R&D news →